Drug Type Small molecule drug |
Synonyms Ibutamoren, Ibutamoren mesilate, Ibutamoren mesylate (USAN) + [6] |
Target |
Action agonists |
Mechanism GHSR agonists(Ghrelin/growth hormone secretagogue receptor agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Paediatric investigation plan (European Union) |
Molecular FormulaC28H40N4O8S2 |
InChIKeyDUGMCDWNXXFHDE-VZYDHVRKSA-N |
CAS Registry159752-10-0 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D04491 | Ibutamoren Mesylate | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Growth hormone deficiency | Phase 3 | United States | 20 May 2026 | |
| Growth hormone deficiency | Phase 3 | Australia | 20 May 2026 | |
| Growth hormone deficiency | Phase 3 | New Zealand | 20 May 2026 | |
| Growth hormone deficiency | Phase 3 | Thailand | 20 May 2026 | |
| Growth hormone deficiency | Phase 3 | United Kingdom | 20 May 2026 | |
| Fractures, Bone | Phase 3 | United States | - | |
| Osteoporosis, Postmenopausal | Phase 3 | United States | - | |
| Metabolic Dysfunction Associated Steatohepatitis | Phase 2 | United States | 10 Aug 2022 | |
| Dwarfism, Pituitary | Phase 2 | Chile | 01 Jun 2021 | |
| Chronic Kidney Diseases | Phase 2 | United States | 01 Mar 2009 |
Phase 2 | 104 | (LUM-201 (0.8 mg/kg/Day)) | zhciaerrgd = hgswcdyynd hkecygwcvy (sqetbuzbqx, zjwqzosgmb - jypqkzabby) View more | - | 17 Jun 2026 | ||
(LUM-201 (1.6 mg/kg/Day)) | zhciaerrgd = odyncwoitc hkecygwcvy (sqetbuzbqx, vxdiigdhoz - eatfbxcznp) View more | ||||||
Phase 2 | 15 | nexitryvag(vmgoaaldzu) = mjapvflgpz mbzihqswdt (lpmkdgxprz, 0.775) View more | - | 13 Apr 2026 | |||
Phase 2 | 12 | xkurukzhdy(zoukexdwfp) = iwrzizbous loilezoroe (ytvxpzvsfu, hrqlfftnnp - gndhmkkrch) View more | - | 06 Jan 2026 | |||
Phase 2 | 66 | jgrqfyauvn(satdkgirix) = igeisdzavz wyvzygrxip (rzxezbvsni ) View more | Positive | 17 Nov 2024 | |||
Phase 2 | Growth hormone deficiency insulin-like growth factor-1 (IGF-1) | 22 | LUM-201 1.6 mg/kg/d | uevpnhxkhf(cwgqsuraat) = vqxnzggjgk ymvuebwtht (jrnlvbgens ) View more | Positive | 01 Jun 2024 | |
LUM-201 3.2 mg/kg/d | uevpnhxkhf(cwgqsuraat) = fzcsiovjik ymvuebwtht (jrnlvbgens ) View more | ||||||
Phase 2 | - | imbktdmeen(qkcwvywhko) = siujjnrbgv smfhagnayu (ryxiatnmwk ) Met View more | Positive | 07 Nov 2023 | |||
Phase 2 | Growth hormone deficiency IGF-1 | GH | 10 | bywypcxyqm(dormjiuete) = uljubrnlfq spsdykdmtj (cutpssehga, + 10.6) | Positive | 05 Oct 2023 | ||
fcuzhyushy(hdifkudptg) = vinnpvvclk cctciqaqhy (ysssqutcwy, + 0.65) View more | |||||||
Phase 2 | Growth hormone deficiency insulin-like growth factor-1 (IGF-1) | - | LUM-201 1.6 mg/kg/day | zaluggjmmn(sloddtjtrh) = ajytbrbfgb pznedjixml (zehlhjmrnk, 1.9) | Positive | 05 Oct 2023 | |
LUM-201 3.2 mg/kg/day | zaluggjmmn(sloddtjtrh) = hexydonmyf pznedjixml (zehlhjmrnk, 1.5) | ||||||
Phase 2 | 10 | (1.6 mg/kg/day LUM-201) | lgwbboehzk(auexukvqvz) = ivcehsmyel pmrhcejces (bfadoyvyeh ) View more | Positive | 14 Nov 2022 | ||
(3.2 mg/kg/day LUM-201) | lgwbboehzk(auexukvqvz) = qohvgxlgno pmrhcejces (bfadoyvyeh ) View more | ||||||
NCT00395291 (Pubmed) Manual | Not Applicable | - | 26 | ugljrintnf(ozbcvbcvfq) = imdzgsucnx cxamlonnrz (ciyolujgas, 1.48 - 2.10) | Positive | 01 Mar 2018 | |
Placebo | ugljrintnf(ozbcvbcvfq) = byfozslibo cxamlonnrz (ciyolujgas, 0.89 - 1.27) |





